etidronate has been researched along with Thrombocytopenia in 8 studies
Etidronic Acid: A diphosphonate which affects calcium metabolism. It inhibits ectopic calcification and slows down bone resorption and bone turnover.
etidronic acid : A 1,1-bis(phosphonic acid) that is (ethane-1,1-diyl)bis(phosphonic acid) having a hydroxy substituent at the 1-position. It inhibits the formation, growth, and dissolution of hydroxyapatite crystals by chemisorption to calcium phosphate surfaces.
Thrombocytopenia: A subnormal level of BLOOD PLATELETS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A potential limitation of rhenium-186-1,1-hydroxyethylidene diphosphonate (186Re-HEDP) therapy in patients with painful bone metastases is thrombocytopenia." | 7.69 | Evaluation of thrombocytopenia in patients treated with rhenium-186-HEDP: guidelines for individual dosage recommendations. ( Blijham, GH; de Klerk, JM; Han, SH; Stokkel, MP; van Dijk, A; van het Schip, AD; van Rijk, PP; Zonnenberg, BA, 1994) |
| " A Phase 1 dosage escalation study was performed using 186Re-HEDP in patients with metastatic breast cancer." | 6.68 | Phase 1 study of rhenium-186-HEDP in patients with bone metastases originating from breast cancer. ( Blijham, GH; de Klerk, JM; Quirijnen, JM; van Dijk, A; van het Schip, AD; van Rijk, PP; Zonnenberg, BA, 1996) |
| "A potential limitation of rhenium-186-1,1-hydroxyethylidene diphosphonate (186Re-HEDP) therapy in patients with painful bone metastases is thrombocytopenia." | 3.69 | Evaluation of thrombocytopenia in patients treated with rhenium-186-HEDP: guidelines for individual dosage recommendations. ( Blijham, GH; de Klerk, JM; Han, SH; Stokkel, MP; van Dijk, A; van het Schip, AD; van Rijk, PP; Zonnenberg, BA, 1994) |
| "Twenty-nine prostatic cancer patients with multiple painful bone metastases were included in the study." | 2.69 | Can bone marrow scintigraphy predict platelet toxicity after treatment with 186Re-HEDP? ( de Klerk, JM; Huiskes, AW; van Dijk, A; van Het Schip, AD; van Rijk, PP; Zonnenberg, BA, 1999) |
| " A Phase 1 dosage escalation study was performed using 186Re-HEDP in patients with metastatic breast cancer." | 2.68 | Phase 1 study of rhenium-186-HEDP in patients with bone metastases originating from breast cancer. ( Blijham, GH; de Klerk, JM; Quirijnen, JM; van Dijk, A; van het Schip, AD; van Rijk, PP; Zonnenberg, BA, 1996) |
| "Although the function of normal bone marrow is affected by metastases in patients with metastatic bone disease, the MIRD model can be used to relate toxicity to the bone marrow absorbed dose after a therapeutic dosage of 186Re-HEDP." | 1.29 | Bone marrow absorbed dose of rhenium-186-HEDP and the relationship with decreased platelet counts. ( Blijham, GH; de Klerk, JM; Hoekstra, A; Rutgers, DH; van Dieren, EB; van Dijk, A; van het Schip, AD; van Rijk, PP; Zonnenberg, BA, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (75.00) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Scheffler, J | 1 |
| Derejko, M | 1 |
| Bandurski, T | 1 |
| Romanowicz, G | 1 |
| de Klerk, JM | 5 |
| Zonnenberg, BA | 5 |
| van het Schip, AD | 5 |
| van Dijk, A | 5 |
| Han, SH | 2 |
| Quirijnen, JM | 2 |
| Blijham, GH | 4 |
| van Rijk, PP | 5 |
| Stokkel, MP | 1 |
| van Dieren, EB | 1 |
| Hoekstra, A | 1 |
| Rutgers, DH | 1 |
| Silberstein, EB | 1 |
| Huiskes, AW | 1 |
| Spencer, RP | 1 |
1 review available for etidronate and Thrombocytopenia
| Article | Year |
|---|---|
Application of rhenium-188 HEDP in bone metastases therapy.
Topics: Bone Neoplasms; Etidronic Acid; Humans; Leukopenia; Organometallic Compounds; Pain; Palliative Care; | 2003 |
4 trials available for etidronate and Thrombocytopenia
| Article | Year |
|---|---|
Dose escalation study of rhenium-186 hydroxyethylidene diphosphonate in patients with metastatic prostate cancer.
Topics: Aged; Bone Neoplasms; Etidronic Acid; Humans; Male; Organometallic Compounds; Palliative Care; Prost | 1994 |
Phase 1 study of rhenium-186-HEDP in patients with bone metastases originating from breast cancer.
Topics: Alkaline Phosphatase; Bone Neoplasms; Breast Neoplasms; Carcinoembryonic Antigen; Dose-Response Rela | 1996 |
Dosage and response in radiopharmaceutical therapy of painful osseous metastases.
Topics: Bone Neoplasms; Breast Neoplasms; Dose-Response Relationship, Radiation; Etidronic Acid; Female; Hum | 1996 |
Can bone marrow scintigraphy predict platelet toxicity after treatment with 186Re-HEDP?
Topics: Aged; Blood Platelets; Bone and Bones; Bone Marrow; Bone Marrow Neoplasms; Diphosphonates; Etidronic | 1999 |
3 other studies available for etidronate and Thrombocytopenia
| Article | Year |
|---|---|
Evaluation of thrombocytopenia in patients treated with rhenium-186-HEDP: guidelines for individual dosage recommendations.
Topics: Aged; Aged, 80 and over; Bone Neoplasms; Dose-Response Relationship, Radiation; Etidronic Acid; Huma | 1994 |
Bone marrow absorbed dose of rhenium-186-HEDP and the relationship with decreased platelet counts.
Topics: Aged; Bone Marrow; Bone Neoplasms; Dose-Response Relationship, Radiation; Etidronic Acid; Humans; Ma | 1996 |
Quantifying leukocyte and thrombocyte suppression-recovery after Re-186 HEDP for bone metastases.
Topics: Blood Platelets; Bone Marrow; Bone Neoplasms; Breast Neoplasms; Carcinoma; Etidronic Acid; Female; F | 2000 |